newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

  • Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia is expected to reach target enrollment of 300 participants in April 2026, with topline results anticipated in Q3 2026.
  • Phase 2 IRIS trial for ML-004 in autism spectrum disorder has completed enrollment of approximately 160 participants, with topline results expected in Q3 2026.
  • The FDA granted Fast Track designation to ML-007C-MA for Alzheimer's disease psychosis, with Phase 2 VISTA trial topline results expected in the second half of 2027.
  • MapLight Therapeutics expanded its pipeline with ML-055, a next-generation M1/M4 muscarinic agonist program, with candidate nomination expected in 2026.
  • The company ended 2025 with $453.1 million in cash, cash equivalents, and investments, sufficient to fund operations through 2027.
  • Research and development expenses totaled $138.3 million for the full year 2025, compared to $68.5 million in 2024, driven by clinical trial costs & stock-based compensation.
  • General & administrative expenses were $30.7 million for the full year 2025, up from $14.4 million in 2024, primarily due to employee-related costs & professional fees.
  • The company reported a net loss of $161.2 million for the full year 2025, compared to a net loss of $77.6 million in 2024.